Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas aeruginosa Pathogenicity and Inflammasome Activation

Journal of Infectious Diseases

Volumn 214, Issue 7, 2016, Pages 1105-1116

  Anantharajah, Ahalieyah ^a   Faure, Emmanuel ^b   Buyck, Julien M ^a,f   Sundin, Charlotta ^c,g   Lindmark, Tuulikki ^c,h   Mecsas, Joan ^d   Yahr, Timothy L ^e   Tulkens, Paul M ^a   Mingeot Leclercq, Marie Paule ^a   Guery, Benoît ^b   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIV LILLE   (France)

^c Creative Antibiotics   (Sweden)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UMEÅ UNIVERSITY   (Sweden)

^h Disruptivematerials   (Sweden)

Author keywords

anti virulence strategy; cytotoxicity; flagellum; inflammasome activation; Pseudomonas aeruginosa; pulmonary infection; type III secretion system

Indexed keywords

ANTIINFECTIVE AGENT; INFLAMMASOME; INP 1855; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; TYPE III SECRETION SYSTEM; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BACTERIAL CLEARANCE; BACTERIAL FLAGELLUM; BACTERIAL VIRULENCE; CELL ADHESION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME RELEASE; HOST PATHOGEN INTERACTION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; TRANSCRIPTION REGULATION; TYPE III SECRETION SYSTEM; ANIMAL; BACTERIAL PNEUMONIA; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PSEUDOMONAS INFECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INFLAMMASOMES; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TYPE III SECRETION SYSTEMS; VIRULENCE FACTORS;

EID: 84994149342     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw295     Document Type: Conference Paper

References (50)

1. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 2009; 37:1777-86.
2. Diepold A, Armitage JP. Type III secretion systems: the bacterial flagellum and the injectisome. Philos Trans R Soc Lond B Biol Sci 2015; 370:20150020.
3. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40: 1157-63.
4. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009; 7:654-65.
5. Miao EA, Ernst RK, Dors M, Mao DP, Aderem A. Pseudomonas aeruginosa activates caspase 1 through Ipaf. Proc Natl Acad Sci U S A 2008; 105:2562-7.
6. Miao EA, Mao DP, Yudkovsky N, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A 2010; 107:3076-80.
7. Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 2007; 204:3235-45.
8. Faure E, Mear JB, Faure K, et al. Pseudomonas aeruginosa type-3 secretion system dampens host defense by exploiting the NLRC4-coupled inflammasome. Am J Respir Crit Care Med 2014; 189:799-811.
9. Cohen TS, Prince AS. Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia. J Clin Invest 2013; 123:1630-7.
10. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 282:L285-90.
11. Yahr TL,Wolfgang MC. Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 2006; 62:631-40.
12. Feldman M, Bryan R, Rajan S, et al. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998; 66:43-51.
13. Blocker A, Komoriya K, Aizawa SI. Type III secretion systems and bacterial flagella: insights into their function from structural similarities. Proc Natl Acad Sci U S A 2003; 100:3027-30.
14. Anantharajah A, Mingeot-Leclercq M-P, Van Bambeke F. Targeting type three secretion system in Pseudomonas aeruginosa. Trends Pharm Sci 2016; doi:10.1016/j. tips.2016.05.11.
15. Enquist PA, Gylfe A, Hagglund U, et al. Derivatives of 8-hydroxyquinoline-antibacterial agents that target intra-and extracellular Gram-negative pathogens. Bioorg Med Chem Lett 2012; 22:3550-3.
16. Anantharajah A, Buyck JM, Faure E, et al. Correlation between cytotoxicity induced by Pseudomonas aeruginosa clinical isolates from acute infections and IL-1beta secretion in a model of human THP-1 monocytes. Pathog Dis 2015; 73:ftv049.
17. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26:171-6.
18. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51:1417-23.
19. Arts IS, Ball G, Leverrier P, et al. Dissecting the machinery that introduces disulfide bonds in Pseudomonas aeruginosa. MBio 2013; 4:e00912-913.
20. Wei Q, Tarighi S, Dotsch A, et al. Phenotypic and genome-wide analysis of an antibiotic-resistant small colony variant (SCV) of Pseudomonas aeruginosa. PLoS One 2011; 6:e29276.
21. Buyck JM, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob Agents Chemother 2013; 57:2310-8.
22. Schuerwegh AJ, Stevens WJ, Bridts CH, De Clerck LS. Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry 2001; 46:172-6.
23. Cai S, Batra S, Wakamatsu N, Pacher P, Jeyaseelan S. NLRC4 inflammasomemediated production of IL-1beta modulates mucosal immunity in the lung against gram-negative bacterial infection. J Immunol 2012; 188:5623-35.
24. Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol Microbiol 1997; 25:1125-39.
25. Sundin C, Henriksson ML, Hallberg B, Forsberg A, Frithz-Lindsten E. Exoenzyme T of Pseudomonas aeruginosa elicits cytotoxicity without interfering with Ras signal transduction. Cell Microbiol 2001; 3:237-46.
26. Coburn J, Frank DW. Macrophages and epithelial cells respond differently to the Pseudomonas aeruginosa type III secretion system. Infect Immun 1999; 67:3151-4.
27. Vinzing M, Eitel J, Lippmann J, et al. NAIP and Ipaf control Legionella pneumophila replication in human cells. J Immunol 2008; 180:6808-15.
28. Zhao Y, Shao F. The NAIP-NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus. Immunol Rev 2015; 265: 85-102.
29. Urbanowski ML, Brutinel ED, Yahr TL. Translocation of ExsE into Chinese hamster ovary cells is required for transcriptional induction of the Pseudomonas aeruginosa type III secretion system. Infect Immun 2007; 75:4432-9.
30. Leong KG, Karsan A. Signaling pathways mediated by tumor necrosis factor alpha. Histol Histopathol 2000; 15:1303-25.
31. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14:1583-9.
32. Rietsch A, Vallet-Gely I, Dove SL, Mekalanos JJ. ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 2005; 102:8006-11.
33. Al Moussawi K, Kazmierczak BI. Distinct contributions of interleukin-1alpha (IL-1alpha) and IL-1beta to innate immune recognition of Pseudomonas aeruginosa in the lung. Infect Immun 2014; 82:4204-11.
34. Arnoldo A, Curak J, Kittanakom S, et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 2008; 4:e1000005.
35. Lee VT, Pukatzki S, Sato H, et al. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2007; 75:1089-98.
36. Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64-73.
37. Patankar YR, Lovewell RR, Poynter ME, Jyot J, Kazmierczak BI, Berwin B. Flagellar motility is a key determinant of the magnitude of the inflammasome response to Pseudomonas aeruginosa. Infect Immun 2013; 81:2043-52.
38. Rosok MJ, Stebbins MR, Connelly K, Lostrom ME, Siadak AW. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa. Infect Immun 1990; 58:3819-28.
39. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264:382-8.
40. Liu PV. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis.3.Identity of the lethal toxins produced in vitro and in vivo. J Infect Dis 1966; 116:481-9.
41. Brutinel ED, Vakulskas CA, Yahr TL. ExsD inhibits expression of the Pseudomonas aeruginosa type III secretion system by disrupting ExsA self-association and DNA binding activity. J Bacteriol 2010; 192:1479-86.
42. McCaw ML, Lykken GL, Singh PK, Yahr TL. ExsD is a negative regulator of the Pseudomonas aeruginosa type III secretion regulon. Mol Microbiol 2002; 46:1123-33.
43. Garrity-Ryan L, Kazmierczak B, Kowal R, Comolli J, Hauser A, Engel JN. The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages. Infect Immun 2000; 68:7100-13.
44. Hauser AR, Fleiszig S, Kang PJ, Mostov K, Engel JN. Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells. Infect Immun 1998; 66:1413-20.
45. Toussaint B, Delic-Attree I, Vignais PM. Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD promoter. Biochem Biophys Res Commun 1993; 196:416-21.
46. Shen DK, Filopon D, Kuhn L, Polack B, Toussaint B. PsrA is a positive transcriptional regulator of the type III secretion system in Pseudomonas aeruginosa. Infect Immun 2006; 74:1121-9.
47. Dacheux D, Attree I, Schneider C, Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infect Immun 1999; 67:6164-7.
48. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/ PopD translocation pore in host cell membranes. Infect Immun 2004; 72: 4741-50.
49. Dasgupta N, Lykken GL, Wolfgang MC, Yahr TL. A novel anti-anti-activator mechanism regulates expression of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 2004; 53:297-308.
50. Davis AJ, Diaz DAD, Mecsas J. A dominant-negative needle mutant blocks type III secretion of early but not late substrates in Yersinia. Mol Microbiol 2010; 76:236-59.